News

Merck & Co. Inc. (NYSE:MRK) on Thursday announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). DME is a serious eye complication of diabetes where high blood sugar damages tiny retinal blood vessels, causing them to leak fluid into the macula (the central part of the retina responsible for sharp vision) and making it swell. BRUNELLO is the first of two Phase 2b/3 trials evaluating remigromig (MK-3000, formerly EYE103), an investigational

Daraxonrasib, the pill touted by a former member of Congress and cancer patient as a ‘miracle drug,’ has been granted approval in patients with pancreatic adenocarcinoma.

MSD has outpaced rivals to market the first PCSK9 inhibitor in pill form for patients with high cholesterol.

The daily medication is expected to be list-priced at $10.50 per pill. Here's what to know about Merck's new cholesterol drug Lipfendra.

Lipfendra, to be taken once a day, is designed to help lower cholesterol levels beyond what statins alone can achieve.

June 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according ‌to letters seen by Reuters.

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]